Literature DB >> 19712862

Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia.

Gokhan Metan1, Fatma Sariguzel, Bulent Sumerkan.   

Abstract

OBJECTIVES: The incidence of multi-drug-resistant (MDR) Acinetobacter strains is increasing and therapeutic options are limited. However, controversy exists regarding the mortality attributable to antimicrobial resistance. The aim of this study was to analyse the clinical features and outcomes of patients with MDR Acinetobacter calcoaceticus-Acinetobacter baumannii complex (Acb complex) bacteraemia and determine the factors influencing survival by using 14-day mortality as the main outcome measure.
METHODS: An observational study was conducted at a tertiary care hospital in Turkey from February 2007 to March 2008. Only one bacteraemic episode from one patient was included in the study.
RESULTS: A total of 100 clinically significant Acb complex bacteraemic episodes were detected. The overall mortality was 63% in 14 days. According to univariate analysis, diabetes mellitus, haematological malignancy, unknown source of bacteraemia, septic shock, resistance to carbapenems, and inappropriate empirical therapy were associated with mortality amongst patients with Acb complex bacteraemia. Multivariate analysis showed that diabetes mellitus (RR, 1.68; 95% CI, 1.22-1.76), carbapenem resistance (RR, 1.63; 95% CI, 1.19-1.89), and septic shock (RR, 1.65; 95% CI, 1.23-1.85) were independent risk factors for 14-day mortality.
CONCLUSION: Although severe underlying diseases play an important role in the clinical outcome of patients with Acb complex bacteraemia, carbapenem resistance and inappropriate therapy are of great concern. Special attention should be paid to infection control practices in the hospitals where MDR Acinetobacter infections are endemic, and well-controlled prospective clinical trials are needed to determine the optimal antimicrobial therapy in critically ill patients suspected of having MDR Acinetobacter bacteraemia. 2009 European Federation of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712862     DOI: 10.1016/j.ejim.2009.05.005

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  34 in total

1.  Morbidity and mortality risk factors in emergency department patients with Acinetobacter baumannii bacteremia.

Authors:  Rui-Xue Sun; Priscilla Song; Joseph Walline; He Wang; Ying-Chun Xu; Hua-Dong Zhu; Xue-Zhong Yu; Jun Xu
Journal:  World J Emerg Med       Date:  2020

2.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

3.  Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii.

Authors:  Sherief El-Shazly; Ali Dashti; Leila Vali; Michael Bolaris; Ashraf S Ibrahim
Journal:  Int J Infect Dis       Date:  2015-10-27       Impact factor: 3.623

4.  Diabetic murine models for Acinetobacter baumannii infection.

Authors:  Guanpingsheng Luo; Brad Spellberg; Teclegiorgis Gebremariam; Michael Bolaris; Hongkyu Lee; Yue Fu; Samuel W French; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2012-03-02       Impact factor: 5.790

5.  Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii.

Authors:  Leticia V Bentancor; Ana Camacho-Peiro; Cagla Bozkurt-Guzel; Gerald B Pier; Tomás Maira-Litrán
Journal:  J Bacteriol       Date:  2012-05-18       Impact factor: 3.490

6.  Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.

Authors:  John S Esterly; Milena Griffith; Chao Qi; Michael Malczynski; Michael J Postelnick; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

7.  Prevalence of and risk factors for multidrug-resistant Acinetobacter baumannii colonization among high-risk nursing home residents.

Authors:  Lona Mody; Kristen E Gibson; Amanda Horcher; Katherine Prenovost; Sara E McNamara; Betsy Foxman; Keith S Kaye; Suzanne Bradley
Journal:  Infect Control Hosp Epidemiol       Date:  2015-06-15       Impact factor: 3.254

8.  Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia.

Authors:  Kevin W Bruhn; Paul Pantapalangkoor; Travis Nielsen; Brandon Tan; Justin Junus; Kristine M Hujer; Meredith S Wright; Robert A Bonomo; Mark D Adams; Wangxue Chen; Brad Spellberg
Journal:  J Infect Dis       Date:  2014-11-05       Impact factor: 5.226

9.  Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.

Authors:  Travis B Nielsen; Paul Pantapalangkoor; Brian M Luna; Kevin W Bruhn; Jun Yan; Ken Dekitani; Sarah Hsieh; Brandon Yeshoua; Bryan Pascual; Evgeny Vinogradov; Kristine M Hujer; T Nicholas Domitrovic; Robert A Bonomo; Thomas A Russo; Magda Lesczcyniecka; Thomas Schneider; Brad Spellberg
Journal:  J Infect Dis       Date:  2017-08-15       Impact factor: 5.226

10.  Copper Resistance of the Emerging Pathogen Acinetobacter baumannii.

Authors:  Caitlin L Williams; Heather M Neu; Jeremy J Gilbreath; Sarah L J Michel; Daniel V Zurawski; D Scott Merrell
Journal:  Appl Environ Microbiol       Date:  2016-09-30       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.